Journal
MABS
Volume 12, Issue 1, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/19420862.2019.1686319
Keywords
Recombinant antibody; control antibody; IgG2; 4; hybrid; therapeutic antibody
Categories
Funding
- Helse Sor-Ost RHF [2018052]
- Norges Forskningsrad [287927, 179573]
- Norwegian council of cardiovascular disease [NCCD-2014]
- Helse Nord RHF [8416/SFP1083-13]
- Odd Fellow Foundation [OFF-2015]
Ask authors/readers for more resources
The mechanism of action of recombinant IgG2/4 antibodies involves blocking of their target without the induction of effector functions. Examples are eculizumab (Soliris (R)), which is used clinically to block complement factor C5, as well as anti-human CD14 (r18D11) and anti-porcine CD14 (rMIL2) produced in our laboratory. So far, no proper IgG2/4 control antibody has been available for controlled validation of IgG2/4 antibody functions. Here, we describe the design of a recombinant control antibody (NHDL), which was generated by combining the variable light (V-L) and heavy (V-H) chains from two unrelated specificities. NHDL was readily expressed and purified as a stable IgG2/4 antibody, and showed no detectable specificity toward any putative antigen present in human or porcine blood. The approach of artificial V-L/V-H combination may be adopted for the design of other recombinant control antibodies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available